Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options

Current Pharmaceutical Biotechnology

Volumn 13, Issue 11, 2012, Pages 2299-2307

  Strik, Herwig M ^a   Kolodziej, Malgorzata ^a   Oertel, Wolfgang ^a   Bäsecke, Jörg ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ST JOSEFS HOSPITAL   (Germany)

Author keywords

Angiogenesis; Apoptosis; Galectin; Glioblastoma; Glioma; Immune response; Therapy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ALKYLATING AGENT; CARMUSTINE; CULLIN; CYTARABINE; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 8; INTERLEUKIN 10; INTERLEUKIN 13; LOMUSTINE; MICROTUBULE ASSOCIATED PROTEIN 2; NIMUSTINE; NITROSOUREA; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P21; PROTEIN P53; TEMOZOLOMIDE; TENIPOSIDE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BLOOD TOXICITY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DOWN REGULATION; GENE SILENCING; GLIOBLASTOMA; GLYCOBIOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOREACTIVITY; MULTICENTER STUDY (TOPIC); NEOPLASM; NONHUMAN; PHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; ANIMAL; BRAIN TUMOR; GLIOMA; METABOLISM;

ANIMALS; BRAIN NEOPLASMS; GALECTINS; GLIOMA; GLYCOMICS; HUMANS;

EID: 84867140573     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802502051     Document Type: Review

References (89)

1. DeAngelis, L. M.; Burger, P. C.; Green, S. B.; Cairncross, J. G. Malignant glioma: Who benefits from adjuvant chemotherapy? Ann. Neurol., 1998, 44, 691-695.
2. Neyns, B.; D'haeseleer, M.; Rogiers, A.; Van de, C. J.; Chaskis, C.; Michorte, A.; Strik, H. The role of cytotoxic drugs in the treatment of central nervous system Gliomas. Acta Neurol. Belg., 2010, 110, 1-14.
3. Hainsworth, J. D.; Ervin, T.; Friedman, E.; Priego, V.; Murphy, P. B.; Clark, B. L.; Lamar, R. E. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer, 2010, 116(15),3663-3669
4. Weller, M.; Muller, B.; Koch, R.; Bamberg, M.; Krauseneck, P. Neuro-oncology working group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J. Clin. Oncol., 2003, 21, 3276-3284.
5. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987-996.
6. Bogler, O.; Weller, M. Apoptosis in gliomas, and its role in their current and future treatment. Front Biosci., 2002, 7, 339-353.
7. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P. L.; Burkhard, C.; Schuler, D.; Probst-Hensch, N. M.; Maiorka, P. C.; Baeza, N.; Pisani, P.; Yonekawa, Y.; Yasargil, M. G.; Lutolf, U. M.; Kleihues, P. Genetic pathways to glioblastoma: a population-based study. Cancer Res., 2004, 64, 6892-6899.
8. Strik, H.; Deininger, M.; Streffer, J.; Grote, E.; Wickboldt, J.; Dichgans, J.; Weller, M.; Meyermann, R. Bcl-2 family protein expression in initial and recurrent glioblastomas: modulation by ra diochemotherapy. J. Neurol. Neurosurg. Psychiat.,1999, 67, 763-768.
9. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352, 997-1003.
10. Wick, A.; Felsberg, J.; Steinbach, J. P.; Herrlinger, U.; Platten, M.; Blaschke, B.; Meyermann, R.; Reifenberger, G.; Weller, M.; Wick, W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol., 2007, 25, 3357-3361.
11. Brandes, A. A.; Tosoni, A.; Cavallo, G.; Bertorelle, R.; Gioia, V.; Franceschi, E.; Biscuola, M.; Blatt, V.; Crino, L.; Ermani, M. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase ii study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br. J. Cancer, 2006, 95, 1155-1160.
12. Strik, H.M.; Buhk, J.H.; Wrede, A.; Hoffmann, A.; Bock, C. Christmann, M.; Kaina, B. Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Mol. Med. Rep., 2008, 1, 863-869.
13. Bolteus, A. J.; Berens, M. E.; Pilkington, G. J. Migration and invasion in brain neoplasms. Curr. Neurol. Neurosci. Rep., 2001, 1, 225-232.
14. Deisboeck, T. S.; Couzin, I. D. Collective behavior in cancer cell populations. Bioessays, 2009, 31, 190-197.
15. Kelly, P. J.; Daumas-Duport, C.; Kispert, D. B.; Kall, B. A.; Scheithauer, B. W.; Illig, J. J. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J. Neurosurg., 1987, 66, 865-874.
16. Evan, G.; Littlewood, T. A matter of life and cell death. Science, 1998, 281, 1317-1322.
17. Wild-Bode, C.; Weller, M.; Wick, W. Molecular determinants of glioma cell migration and invasion. J. Neurosurg., 2001, 94, 978-984.
18. He, Q.; Li, G.; Su, Y.; Shen, J.; Liu, Q.; Ma, X.; Zhao, P.; Zhang, J. Single minded 2-s (SIM2-s) gene is expressed in human GBM cells and involved in GBM invasion. Cancer Biol. Ther., 2010, 9, 430-436.
19. Fischer, I.; Gagner, J. P.; Law, M.; Newcomb, E. W.; Zagzag, D. Angiogenesis in gliomas: Biology and molecular pathophysiology. Brain Pathol., 2005, 15, 297-310.
20. Strik, H. M.; Schluesener, H. J.; Seid, K.; Meyermann, R.; Deininger, M. H. Localization of endostatin in rat and human gliomas. Cancer, 2001, 91, 1013-1019.
21. Wesseling, P.; Ruiter, D. J.; Burger, P. C. Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neurooncol., 1997, 32, 253-265.
22. Riva, M.; Imbesi, F.; Beghi, E.; Galli, C.; Citterio, A.; Trapani, P.; Sterzi, R.; Collice, M. Temozolomide and thalidomide in the treatment of glioblastoma multiforme. Anticancer Res., 2007, 27, 1067-1071.
23. Van Meir, E. G.; Hadjipanayis, C. G.; Norden, A. D.; Shu, H. K.; Wen, P. Y.; Olson, J. J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin., 2010, 60, 166-193.
24. Graeber, M. B.; Scheithauer, B. W.; Kreutzberg, G. W. Microglia in Brain Tumors. Glia, 2002, 40, 252-259.
25. Platten, M.; Kretz, A.; Naumann, U.; Aulwurm, S.; Egashira, K.; Isenmann, S.; Weller, M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol., 2003, 54, 388-392.
26. Parney, I. F.; Hao, C.; Petruk, K. C. Glioma immunology and immunotherapy. Neurosurgery, 2000, 46, 778-791.
27. Wischhusen, J.; Jung, G.; Radovanovic, I.; Beier, C.; Steinbach, J. P.; Rimner, A.; Huang, H.; Schulz, J. B.; Ohgaki, H.; Aguzzi, A.; Rammensee, H. G.; Weller, M. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res., 2002, 62, 2592-2599.
28. Wischhusen, J.; Schneider, D.; Mittelbronn, M.; Meyermann, R.; Engelmann, H.; Jung, G.; Wiendl, H.; Weller, M. Death receptormediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J. Neuroimmunol., 2005, 162, 28-42.
29. Kito, T.; Kuroda, E.; Yokota, A.; Yamashita, U. Enhancement of macrophage cytotoxicity against murine gliomas by interferon beta: increase in nitric oxide production in response to glioma-derived soluble factors. J Neurosurg., 2002, 97, 619-626.
30. Kito, T.; Kuroda, E.; Yokota, A.; Yamashita, U. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-gamma-regulated nitric oxide. J. Neurosurg., 2003, 98, 385-392.
31. Yamanaka, R.; Homma, J.; Yajima, N.; Tsuchiya, N.; Sano, M.; Kobayashi, T.; Yoshida, S.; Abe, T.; Narita, M.; Takahashi, M.; Tanaka, R. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin. Cancer Res., 2005, 11, 4160-4167.
32. Steiner, H. H.; Bonsanto, M. M.; Beckhove, P.; Brysch, M.; Geletneky, K.; Ahmadi, R.; Schuele-Freyer, R.; Kremer, P.; Ranaie, G.; Matejic, D.; Bauer, H.; Kiessling, M.; Kunze, S.; Schirrmacher, V.; Herold-Mende, C. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol., 2004, 22, 4272-4281.
33. Choi, B. D.; Archer, G. E.; Mitchell, D. A.; Heimberger, A. B.; McLendon, R. E.; Bigner, D. D.; Sampson, J. H. EGFRvIIItargeted vaccination therapy of malignant glioma. Brain Pathol., 2009, 19, 713-723.
34. Li, G.; Mitra, S.; Wong, A. J. The epidermal growth factor variant iii peptide vaccine for treatment of malignant gliomas. Neurosurg. Clin. N. Am., 2010, 21, 87-93.
35. Kaltner, H.; Gabius, H. J. Animal lectins: from initial description to elaborated structural and functional classification. Adv. Exp. Med. Biol., 2001, 491, 79-94.
36. Perillo, N. L.; Marcus, M. E.; Baum, L. G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol. Med., 1998, 76, 402-412.
37. Yang, R. Y.; Rabinovich, G. A.; Liu, F. T. Galectins: structure, function and therapeutic potential. Expert. Rev. Mol. Med., 2008, 10, e17.
38. Liu, F. T. S-Type mammalian lectins in allergic inflammation. Immunol. Today, 1993, 14, 486-490.
39. Yang, R. Y.; Hsu, D. K.; Liu, F. T. Expression of galectin-3 modulates t-cell growth and apoptosis. Proc. Natl. Acad. Sci. USA, 1996, 93, 6737-6742.
40. Liu, F. T.; Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer, 2005, 5, 29-41.
41. Lahm, H.; Andre, S.; Hoeflich, A.; Kaltner, H.; Siebert, H. C.; Sordat, B.; der Lieth, C. W.; Wolf, E.; Gabius, H. J. Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj. J., 2004, 20, 227-238.
42. Gunnersen, J.; Spirkoska, V.; Smith, P.; Danks, R.; Tan, S. Growth and migration markers of of rat C6 glioma cells identified by serial analysis of gene expression. Glia, 2000, 32, 146-154.
43. Yamaoka, K.; Mishima, K.; Nagashima, Y.; Asai, A.; Sanai, Y.; Kirino, T. Expression of galectin-1 mrna correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J. Neurosci., Res. 2000, 59, 722-730.
44. Rorive, S.; Belot, N.; Decaestecker, C.; Lefranc, F.; Gordower, L.; Micik, S.; Maurage, C.; Kaltner, H.; Ruchoux, M. M.; Danguy, A.; Gabius, H. J.; Salmon, I.; Kiss, R.; Camby, I. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia, 2001, 33, 241-255.
45. Strik, H. M.; Deininger, M. H.; Frank, B.; Schluesener, H. J.; Meyermann, R. Galectin-3: cellular distribution and correlation with who-grade in human gliomas. J. Neurooncol., 2001, 53, 13-20.
46. Strik, H. M.; Schmidt, K.; Lingor, P.; Tonges, L.; Kugler, W.; Nitsche, M.; Rabinovich, G. A.; Bähr, M. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol. Rep., 2007, 18, 483-488.
47. Satelli, A.; Rao, P.S.; Gupta, P.K.; Lockman, P.R.; Srivenugopal, K.S.; Rao, U.S. Varied expression and localization of multiple galectins in different cancer cell lines. Oncol. Rep., 2008, 19, 587-594.
48. Camby, I.; Decaestecker, C.; Gordower, L.; DeDecker, R.; Kacem, Y.; Ledmmers, A.; Siebert, H.; Bovin, N.; Wesseling, P.; Danguy, A.; Salmon, I.; Gabius, H. J.; Kiss, R. Distinct differences in binding capacity to saccharide epitopes in supratentorial pilocytic astro cytomas, astrocytomas, anaplastic astrocytomas and glioblastomas. J. Neuropath. Exp. Neurol., 2001, 60, 75-84.
49. Puchades, M.; Nilsson, C. L.; Emmett, M. R.; Aldape, K. D.; Ji, Y.; Lang, F. F.; Liu, T. J.; Conrad, C. A. Proteomic investigation of glioblastoma cell lines treated with wild-type P53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and P53 expression. J. Proteome. Res., 2007, 6, 869-875.
50. Camby, I.; Belot, N.; Lefranc, F.; Sadeghi, N.; de Launoit, Y.; Kaltner, H.; Musette, S.; Darro, F.; Danguy, A.; Salmon, I.; Gabius, H. J.; Kiss, R. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to he actin cytoskeleton and levels of expression of small GTPases. J. Neuropath. Exp. Neurobiol., 2002, 61, 585-596.
51. Camby, I.; Belot; Rorive, S.; Lefranc, F.; Lahm, H.; Kaltner, H.; Hadari, Y.; Ruchoux, M. M.; Brotchi, J.; Zick, Y.; Salmon, I.; Gabius, H. J.; Kiss, R. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol., 2001, 11, 12-26.
52. Jung, T. Y.; Jung, S.; Ryu, H. H.; Jeong, Y. I.; Jin, Y. H.; Jin, S. G.; Kim, I. Y.; Kang, S. S.; Kim, H. S. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J. Neurosurg., 2008, 109, 273-284.
53. Fortin, S.; Le Mercier, M.; Camby, I.; Spiegl-Kreinecker, S.; Berger, W.; Lefranc, F.; Kiss, R. Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrinbeta1 in glioblastoma cells. Brain Pathol., 2010, 20, 39-49.
54. Rubinstein, N.; Ilarregui, J. M.; Toscano, M. A.; Rabinovich, G. A. The role of galectins in the initiation, amplification and resolution of inflammatory response. Tissue Antigens, 2004, 64, 1-12.
55. Rubinstein, N.; Alvarez, M.; Zwirner, N. W.; Toscano, M. A.; Ilarregui, J. M.; Bravo, A.; Mordoh, J.; Fainboim, L.; Podhajcer, O. L.; Rabinovich, G. A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened t cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5, 241-251.
56. Strik, H.; Huelper, P.; Erdlenbruch, B.; Meier, J.; Kowalewski, A.; Hemmerlein, B.; Gold, R.; Baehr, M. Experimental models of monocytic infiltration into glioma cell aggregates. Anticancer Res., 2006, 26, 837-842.
57. Le Mercier, M.; Lefranc, F.; Mijatovic, T.; Debeir, O.; Haibe-Kains, B.; Bontempi, G.; Decaestecker, C.; Kiss, R.; Mathieu, V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol. Appl. Pharmacol., 2008, 229, 172-183.
58. Le Mercier, M.; Fortin, S.; Mathieu, V.; Roland, I.; Spiegl-Kreinecker, S.; Haibe-Kains, B.; Bontempi, G.; Decaestecker, C.; Berger, W.; Lefranc, F.; Kiss, R. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia, 2009, 11, 485-496.
59. Le Mercier, M.; Mathieu, V.; Haibe-Kains, B.; Bontempi, G.; Mijatovic, T.; Decaestecker, C.; Kiss, R.; Lefranc, F. Knocking down galectin 1 in human Hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J. Neuropathol. Exp. Neurol., 2008, 67, 456-469.
60. Bresalier, R. S.; Yan, P. S.; Byrd, J. C.; Lotan, R.; Raz, A. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer, 1997, 80, 776-787.
61. Gordower, L.; Decaestecker, Y.; Kacem, Y.; Lemmers, J.; Gusman, J.; Burchert, M.; Danguy, A.; Gabius, H. J.; Salmon, R.; Camby, I. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol. Appl. Neurobiol., 1999, 25, 319-330.
62. Tews, D. S.; Nissen, A. Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis, 1998, 18, 271-284.
63. Roggendorf, W.; Strupp, S.; Paulus, W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. Berl. 1996, 92, 288-293.
64. Liu, F. T.; Hsu, D. K.; Zuberi, R. I.; Kuwabara, I.; Chi, E. Y.; Henderson-WR, J. Expression and function of galectin-3, a betagalactoside-binding lectin, in human monocytes and macrophages. Am. J Pathol., 1995, 147, 1016-1028.
65. Kuklinski, S.; Pesheva, P.; Heimann, C.; Urschel, S.; Gloor, S.; Graeber, S.; Herzog, V.; Pietsch, T.; Wiestler, O. D.; Probstmeier, R. Expression pattern of galectin-3 in neural tumor cell lines. J. Neurosci. Res., 2000, 60, 45-57.
66. Neder, L.; Marie, S. K.; Carlotti, C. G., Jr.; Gabbai, A. A.; Rosemberg, S.; Malheiros, S. M.; Siqueira, R. P.; Oba-Shinjo, S. M.; Uno, M.; Aguiar, P. H.; Miura, F.; Chammas, R.; Colli, B. O.; Silva, W. A., Jr.; Zago, M. A. Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol., 2004, 14, 399-405.
67. Nangia, M. P.; Honjo, Y.; Sarvis, R.; Akahani, S.; Hogan, V.; Pienta, K. J.; Raz, A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol., 2000, 156, 899-909.
68. Fukushi, J.; Makagiansar, I. T.; Stallcup, W. B. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin3 and alphabeta1 integrin. Mol. Biol. Cell, 2004, 15, 3580-3590
69. Wen, Y.; Makagiansar, I. T.; Fukushi, J.; Liu, F. T.; Fukuda, M. N.; Stallcup, W. B. Molecular basis of interaction between NG2 proteoglycan and galectin-3. J. Cell Biochem., 2006, 98, 115-127.
70. Vladimirova, V.; Waha, A.; Luckerath, K.; Pesheva, P.; Probstmeier, R. Runx2 Is expressed in human glioma cells and mediates the expression of galectin-3. J. Neurosci. Res., 2008, 86, 2450-2461.
71. Debray, C.; Vereecken, P.; Belot, N.; Teillard, P.; Brion, J. P.; Pandolfo, M.; Pochet, R. Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem. Biophys. Res. Commun., 2004, 325, 1393-1398.
72. McClung, H. M.; Thomas, S. L.; Osenkowski, P.; Toth, M.; Menon, P.; Raz, A.; Fridman, R.; Rempel, S. A. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci. Lett., 2007, 419, 172-177.
73. Wei, J.; Barr, J.; Kong, L. Y.; Wang, Y.; Wu, A.; Sharma, A. K.; Gumin, J.; Henry, V.; Colman, H.; Sawaya, R.; Lang, F. F.; Heimberger, A. B. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res., 2010, 16, 461-473.
74. Mathieu, V.; Le Mercier, M.; De Neve, N.; Sauvage, S.; Gras, T.; Roland, I.; Lefranc, F.; Kiss, R. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J. Invest Dermatol., 2007, 127(10), 2399-2410
75. Inohara, H.; Akahani, S.; Raz, A. Galectin-3 stimulates cell proliferation. Exp. Cell Res., 1998, 245, 294-302.
76. Akahani, S.; Nangia, M. P.; Inohara, H.; Kim, H. R.; Raz, A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res., 1997, 57, 5272-5276.
77. Giese, A.; Bjerkvig, R.; Berens, M. E.; Westphal, M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol., 2003, 21, 1624-1636.
78. Makagiansar, I. T.; Williams, S.; Mustelin, T.; Stallcup, W. B. Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J. Cell Biol., 2007, 178, 155-165.
79. Thijssen, V. L.; Postel, R.; Brandwijk, R. J.; Dings, R. P.; Nesmelova, I.; Satijn, S.; Verhofstad, N.; Nakabeppu, Y.; Baum, L. G.; Bakkers, J.; Mayo, K. H.; Poirier, F.; Griffioen, A. W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. USA, 2006, 103, 15975-15980.
80. Perillo, N. L.; Pace, K. E.; Seilhamer, J. J.; Baum, L. G.; Sato, S.; Hughes, R. C. Apoptosis of T cells mediated by galectin-1. Nature, 1995, 378, 736-739.
81. Rainov, N. G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 2000, 11, 2389-2401.
82. Wild-Bode, C.; Weller, M.; Rimner, A.; Dichgans, J.; Wick, W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res., 2001, 61, 2744-2750.
83. Le, Q. T.; Shi, G.; Cao, H.; Nelson, D. W.; Wang, Y.; Chen, E. Y.; Zhao, S.; Kong, C.; Richardson, D.; O'Byrne, K. J.; Giaccia, A. J.; Koong, A. C. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol., 2005, 23, 8932-8941.
84. Rabinovich, G. A.; Cumashi, A.; Bianco, G. A.; Ciavardelli, D.; Iurisci, I.; D'Egidio, M.; Piccolo, E.; Tinari, N.; Nifantiev, N.; Ia cobelli, S. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectinmediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology, 2006, 16, 210-220.
85. Sorme, P.; Kahl-Knutsson, B.; Wellmar, U.; Magnusson, B. G.; Leffler, H.; Nilsson, U. J. Design and synthesis of galectin inhibitors. Methods Enzymol., 2003, 363, 157-169.
86. Andre, S.; Pieters, R. J.; Vrasidas, I.; Kaltner, H.; Kuwabara, I.; Liu, F. T.; Liskamp, R. M.; Gabius, H. J. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. Chembiochem., 2001, 2, 822-830.
87. Ingrassia, L.; Camby, I.; Lefranc, F.; Mathieu, V.; Nshimyumukiza, P.; Darro, F.; Kiss, R. Anti-galectin compounds as potential anticancer drugs. Curr. Med. Chem., 2006, 13, 3513-3527.
88. Le Mercier, M.; Fortin, S.; Mathieu, V.; Kiss, R.; Lefranc, F. Galectins and gliomas. Brain Pathol., 2010, 20, 17-27.
89. Nangia, M. P.; Sarvis, R.; Visscher, D. W.; Bailey, P. J.; Raz, A.; Sarkar, F. H. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res. Treat., 1998, 49, 171-183.